I first encountered CA: A Cancer Journal for Clinicians as a medical student. Back then, the American Cancer Society (ACS) printed hundreds of thousands of copies that were mailed (without any charge) to practicing physicians and dropped off by ACS volunteers at medical schools, with the goals of educating students about cancer and inspiring some of us to pursue careers in cancer-related specialties. I recall appreciating that the Society deemed medical students worthy of their attention. After carrying each issue in the pocket of my short white medical student coat for a few days (back when the journal was printed in a small, digest-sized format), I realized that I was unlikely to get beyond the first few pages anytime soon, so I carefully separated the journal pages and filed the articles in folders labeled by topic, wishing that someday I would be able to read them. (Note—foreshadowing alert).

After 2 decades of pathology residency, fellowship, academic pathology practice, and laboratory-based cancer research, this wish came true. A series of fortunate events led me to a staff position at the ACS national office, where one of my roles was reading CA: A Cancer Journal for Clinicians. Every article. At least twice. For more than 20 years.

The first message of this editorial is my retirement from the position of Editor. This role has been tremendously fulfilling and enjoyable, but it's time for some new ideas from someone else. By the time you read this I will be almost completely retired from my work with the ACS and looking forward to some other pursuits that, until recently, I haven't had time for.

More importantly, this editorial also gives me an opportunity for some reflection about this journal, to thank the people who are responsible for its success, and to introduce the incoming editor, Don Dizon, MD. It would be difficult to name all the distinguished contributors to CA during my tenure as Editor, so I apologize for any truncations in the lists below and for any omissions resulting from lapses in my memory. There are several individuals who have contributed to CA in more than one capacity, and many of them are included below on only one list (the one for which their role seems most significant or most memorable to me). I appreciate them all and extend my utmost gratitude for their expertise and time.

CA reaches a heterogeneous audience of clinical and public health professionals to provide information relevant to the entire cancer continuum, from prevention through survivorship and end-of-life care. Content includes educational review articles; ACS guidelines for cancer prevention and early detection; ACS summaries of the most recent data on cancer incidence, mortality, risk factors, and screening prevalence; virtual tumor board discussions; and brief news stories that offer perspectives on recent research. CA has always been free to access and remains free online without subscription.

Published since 1950 by the ACS, CA: A Cancer Journal for Clinicians is one of the oldest peer-reviewed journals in oncology and retains the highest impact factor of all journals ranked by the Institute for Scientific Information (now, Clarivate Analytics). Much has changed since that first issue. Younger readers may be shocked to learn that this journal's name CA comes from the term that was used long ago in discussions among clinicians to avoid patients overhearing the word cancer, in the belief that diagnostic disclosure would have a negative impact on the patient's quality of life. In some superficial ways, CA has also changed substantially since my early years as Editor, when manuscripts were submitted via postal mail (not even e-mail) with triplicate copies of the text and photographic prints of graphs and figures to be forwarded to reviewers (also via postal mail). The first online issue of CA was in 2007, and, since 2020, publication has been online only. Nonetheless, the essence of CA has remained remarkably consistent—to provide educational content that advances the ACS goals of reducing cancer incidence and mortality rates and improving quality of life for cancer survivors.

The main activity of most journal editors is prioritizing a large number of unsolicited research reports to select a relatively small proportion that will be accepted for publication. In contrast, most CA review articles begin at a meeting of our Associate Editors and Editorial Board members. These experts in various aspects of cancer care and research recommend and discuss topics that they deem most likely to advance the ACS mission and to be relevant to our readers' interests. The success of this journal depends to a great degree on the outstanding expertise, insight, and dedication of our Associate Editors and Editorial Board. It has been an honor to work with these all-stars of the cancer world. I sincerely appreciate Durado Brooks, MD, MPH; Keith Delman, MD; and Charles R. Thomas, Jr., MD, who served the journal as Associate Editors during my term as Editor, and everyone who served on our Editorial Board between 2000 and 2023, including the following list of current Editorial Board members: Gini Fleming, MD; Frederick Greene, MD; Ahmedin Jemal, DVM, PhD; Cathy Meade, PhD, RN; Kevin Oeffinger, MD; Alpa Patel, PhD; Nancy Perrier, MD; Charles R. Thomas, Jr., MD; and Andrew Vickers, PhD.

If you look at the CA masthead webpage, you will see an Editor and an Editor-in-Chief. The latter, historically, has generally been the ACS Chief Medical/Scientific Officer (or a similar high-ranking executive position). These leaders are usually too busy with their myriad responsibilities to get involved with decisions regarding most individual articles. However, all Editors-in-Chief during my tenure—Harmon Eyre, MD; Otis W. Brawley, MD; and Arif Kamal, MD, MBA, MHS—made vital contributions to the journal's direction and strategy and, importantly, provided wise advice regarding some challenging editorial situations that I have encountered over the years.

My next thank you goes to the authors of CA articles. Writing is much more difficult than editing, and the depth and breadth of CA review articles is not easily or quickly accomplished. Although there are far too many authors of CA reviews for me to thank individually, I sincerely appreciate them taking time from their busy schedules of patient care, research, teaching, and/or administrative work to contribute one or more articles to CA. Moreover, it is my impression that, because time spent writing review articles usually does not provide as much career advancement per hour of effort as research articles do, their willingness to undertake this work reflects genuine dedication to the continuing education of our audience, and I applaud our authors for their commitment and contribution.

There are two categories of CA articles that make an especially prominent contribution to CA's identity. The first is the cancer statistics series of articles. Countless scientists have worked on these, but I want to highlight the ACS staff leaders who have directed this endeavor during my editorial tenure: Ahmedin Jemal, DVM, PhD (again); Rebecca L. Siegel, MPH; Elizabeth Ward, PhD; and Michael Thun, MD, MS. Cancer prevention and screening guidelines are the other special category of CA articles. Again, there are far too many staff and volunteer co-authors for me to list comprehensively, but I want to give special thanks to ACS staff who have led guideline teams during my years as Editor: Durado Brooks, MD, MPH (again); Colleen Doyle, MS, RD; Debbie Saslow, PhD; and Robert Smith, PhD.

Anyone who has worked in journal editing knows how important managing editors are, and I appreciate the excellence of the outstanding professionals in that role during my tenure as Editor. I especially want to individually thank the current managing editor, Ms. Jin Kim and her immediate predecessor, Ms. Carissa Gilman. Their competence, efficiency, judgment, and organization are unrivaled. I cannot begin to explain how much they helped me and how much I enjoyed working with them. One step higher on the organizational chart, the ACS journal and/or publishing department leaders have also had a tremendously positive impact on CA. Among other contributions, they have the difficult task of reconciling editors' dreams (or delusions) with their organization's business realities. Special thanks to Ms. Esmeralda Galán Buchanan and, before her, Ms. Diane Scott-Lichter and Ms. Emily Pualwan.

Our publishers, John Wiley & Sons, Inc. (2008 to present), and Lippincott (2000–2010), have been important partners in distributing our content to our audience, and their ongoing innovation has made our online content delivery more effective and efficient.

Finally, this journal would be meaningless without you, our readers. Thank you for your page views and citations that justify our existence. More importantly, thank you for using the information in CA articles to inform your clinical care and your research.

Editing CA is not a full-time job. Although this paragraph is a little tangential to the theme of this editorial, I want to allocate a few words to thanking the leaders, mentors, and colleagues who made the remaining percentages of my years with ACS so fulfilling and satisfying. From the ACS department that provides patient information and services, special thanks to Mr. Chuck Westbrook and Ms. Terry Music, and to all of my colleagues who led, guided, and contributed to writing, editing, and distributing the Society's information about all aspects of cancer to patients, their families and friends, and the general public. From the ACS research department, a very sincere thank you to all of my colleagues, and especially to Elizabeth Ward, PhD (again), Susan Gapstur, PhD, and Ahmedin Jemal, DVM, PhD (again), for welcoming me into their research teams, and to Eric Jacobs, PhD, and Stacey Fedewa, MPH, PhD, my most frequent colleagues and mentors in analytic epidemiology and surveillance research, respectively.

And finally, as we approach the end of this editorial and the end of my term as CA Editor, I am delighted to introduce the incoming Editor, Don Dizon, MD. Dr. Dizon is a highly respected oncologist who specializes in women's cancers and holds leadership positions at Lifespan Cancer Institute and the Legorreta Cancer Center at Brown University. In addition to his impressive clinical and research background, Dr. Dizon comes to this position with significant editorial expertise, including a 10-year term as Editor-in-Chief of the American Society of Clinical Oncology education book, a peer-reviewed, PubMed-indexed publication. He has the expertise, creativity, and vision that make him the excellent selection as CA's newest Editor. I am certain of CA's future success under Dr. Dizon's leadership alongside the current Editor-in-Chief, Arif Kamal, MD, and look forward to reading future articles online (although maybe not twice) as a reader instead of an Editor.

我第一次遇到CA：临床医生的癌症杂志作为一名医学生。当时，美国癌症协会 (ACS) 印制了数十万份邮寄（免费）给执业医师，并由医学院的 ACS 志愿者投递，目的是对学生进行癌症教育并激励我们中的一些人从事癌症相关专业的职业。我记得很感激学会认为医学生值得他们关注。在我把每一期都放在我的白色医学生短外套的口袋里几天后（当期刊以小的、摘要大小的格式印刷时），我意识到我不太可能很快就读完前几页，所以我小心翼翼地将期刊页面分开，并将文章归档在按主题标记的文件夹中，希望有一天我能够阅读它们。（注——预示警报）。

经过 2 年的病理学住院医师、研究员、学术病理学实践和基于实验室的癌症研究，这个愿望实现了。一系列幸运事件使我成为了 ACS 国家办公室的一名职员，我的职责之一是阅读CA：临床医生的癌症杂志。每篇文章。至少两次。20 多年来。

这篇社论的第一条信息是我从编辑的职位上退休。这个角色非常充实和愉快，但现在是时候听取其他人的一些新想法了。当你读到这篇文章时，我将几乎完全从 ACS 的工作中退休，并期待着一些其他的追求，直到最近，我还没有时间去做。

更重要的是，这篇社论也让我有机会反思这本杂志，感谢为它的成功负责的人，并介绍即将上任的编辑 Don Dizon，医学博士。在我担任编辑期间，很难说出CA的所有杰出贡献者的名字，因此对于以下列表中的任何截断以及由于我的记忆失误而导致的任何遗漏，我深表歉意。有几个人以不止一种身份为 CA 做出了贡献，其中许多人仅包含在下面的一个列表中（他们的作用对我来说似乎最重要或最难忘的列表）。我感谢他们所有人，并对他们的专业知识和时间表示由衷的感谢。

CA接触到临床和公共卫生专业人员的不同受众，提供与整个癌症连续体相关的信息，从预防到生存和临终关怀。内容包括教育评论文章；ACS 癌症预防和早期检测指南；关于癌症发病率、死亡率、危险因素和筛查流行率的最新数据的 ACS 摘要；虚拟肿瘤委员会讨论；以及对近期研究提供观点的简短新闻报道。CA一直可以免费访问，并且无需订阅即可免费在线使用。

自 1950 年以来由 ACS 出版，CA：A Cancer Journal for Clinicians是肿瘤学领域最古老的同行评审期刊之一，在科学信息研究所（现为 Clarivate Analytics）排名的所有期刊中保持最高影响因子。自第一期以来发生了很大变化。年轻的读者可能会惊讶地发现，该期刊的名称CA来自很久以前临床医生讨论时使用的术语，以避免患者无意中听到癌症这个词，因为他们相信诊断披露会对患者的生活质量产生负面影响. 在某些表面上，CA自从我早年担任编辑以来也发生了重大变化，当时通过邮寄（甚至不是电子邮件）提交手稿，并附上一式三份的文本和图形和数字的照片打印件，以转发给审稿人（也通过邮寄）。CA的第一期在线发行于 2007 年，自 2020 年起，仅在线出版。尽管如此， CA的本质仍然非常一致——提供教育内容以推进 ACS 降低癌症发病率和死亡率以及改善癌症幸存者生活质量的目标。

大多数期刊编辑的主要活动是优先处理大量未经请求的研究报告，以选择相对较小的比例来接受发表。相比之下，大多数CA评论文章从我们的副主编和编辑委员会成员的会议开始。这些癌症护理和研究各个方面的专家推荐和讨论他们认为最有可能推进 ACS 使命并与我们读者的兴趣相关的主题。本刊的成功在很大程度上取决于我们的副主编和编辑委员会杰出的专业知识、洞察力和奉献精神。很荣幸能与这些癌症界的全明星一起工作。我衷心感谢 Durado Brooks，医学博士，公共卫生硕士；医学博士 Keith Delman；和 Charles R. Thomas, Jr., MD，他在我担任编辑期间担任该杂志的副主编，以及 2000 年至 2023 年间在我们编辑委员会任职的所有人，包括以下现任编辑委员会成员名单：Gini Fleming，医学博士；医学博士 Frederick Greene；Ahmedin Jemal，DVM，博士；Cathy Meade，博士，注册护士；凯文·奥芬格，医学博士；阿尔帕·帕特尔博士；医学博士 Nancy Perrier；小查尔斯·R·托马斯，医学博士；和 Andrew Vickers 博士。

如果您查看CA刊头网页，您会看到一位编辑和一位主编。从历史上看，后者通常是 ACS 首席医疗/科学官（或类似的高级行政职位）。这些领导人通常忙于承担无数的责任，而无暇参与有关大多数个别文章的决策。但是，我任职期间的所有主编——Harmon Eyre，医学博士；Otis W. Brawley，医学博士；和 Arif Kamal，MD、MBA、MHS——对期刊的方向和战略做出了重要贡献，重要的是，他们就我多年来遇到的一些具有挑战性的编辑情况提供了明智的建议。

我接下来要感谢CA文章的作者。写作比编辑难得多，CA评论文章的深度和广度不是轻易或快速完成的。虽然CA评论的作者太多，我无法一一感谢，但我衷心感谢他们从繁忙的患者护理、研究、教学和/或行政工作中抽出时间为CA贡献一篇或多篇文章. 此外，我的印象是，由于花在撰写评论文章上的时间通常无法像研究文章那样每小时的努力提供那么多的职业发展，他们愿意从事这项工作反映了他们对我们读者继续教育的真诚奉献，我为我们的作者的承诺和贡献鼓掌。

有两类CA文章对CA的身份做出了特别突出的贡献。首先是癌症统计系列文章。无数科学家都在研究这些，但我想强调在我的编辑任期内指导这项工作的 ACS 工作人员领导：Ahmedin Jemal，DVM，博士（再次）；Rebecca L. Siegel，每小时英里数；伊丽莎白·沃德博士；和 Michael Thun，医学博士，硕士。癌症预防和筛查指南是CA的另一个特殊类别文章。再一次，有太多的工作人员和志愿合著者让我无法全面列出，但我要特别感谢在我担任编辑期间领导指南团队的 ACS 工作人员：Durado Brooks，MD，MPH（再次）；Colleen Doyle，硕士，研发；黛比·萨斯洛博士；和罗伯特史密斯博士。

任何从事期刊编辑工作的人都知道执行编辑的重要性，我很欣赏在我担任编辑期间担任该职位的杰出专业人士的卓越表现。我要特别感谢现任执行主编 Jin Kim 女士和她的前任 Carissa Gilman 女士。他们的能力、效率、判断力和组织能力是无与伦比的。我无法开始解释他们对我的帮助有多大，以及我有多喜欢与他们一起工作。在组织结构图上更上一层楼，ACS 期刊和/或出版部门的领导也对CA产生了巨大的积极影响. 在其他贡献中，他们的艰巨任务是协调编辑的梦想（或错觉）与组织的业务现实。特别感谢 Esmeralda Galán Buchanan 女士，以及在她之前的 Diane Scott-Lichter 女士和 Emily Pualwan 女士。

我们的出版商 John Wiley & Sons, Inc.（2008 年至今）和 Lippincott（2000-2010 年）一直是向我们的受众分发我们内容的重要合作伙伴，他们不断的创新使我们的在线内容交付更加有效和高效.

最后，如果没有您，我们的读者，这本杂志将毫无意义。感谢您的页面浏览量和引用证明了我们的存在。更重要的是，感谢您使用CA文章中的信息为您的临床护理和研究提供信息。

编辑CA不是全职工作。虽然这一段与这篇社论的主题有点无关，但我想用几句话来感谢领导、导师和同事，是他们让我在 ACS 的剩余时间里如此充实和满足。来自提供患者信息和服务的 ACS 部门，特别感谢 Chuck Westbrook 先生和 Terry Music 女士，以及领导、指导并为撰写、编辑和分发协会各方面信息做出贡献的所有同事癌症对患者、他们的家人和朋友以及公众的影响。来自 ACS 研究部门，非常真诚地感谢我的所有同事，尤其是 Elizabeth Ward 博士（再次）、Susan Gapstur 博士和 Ahmedin Jemal，DVM，博士（再次）欢迎我参与他们的研究团队，

最后，当我们接近这篇社论的结尾和我作为CA编辑的任期即将结束时，我很高兴地介绍即将上任的编辑 Don Dizon，医学博士。Dizon 博士是一位备受尊敬的肿瘤学家，专门研究女性癌症，并在布朗大学 Lifespan 癌症研究所和 Legorreta 癌症中心担任领导职务。除了令人印象深刻的临床和研究背景外，Dizon 博士担任这一职位还具有重要的编辑专业知识，包括担任美国临床肿瘤学会教育书籍的 10 年主编，这是一本同行评审的 PubMed -索引出版物。他的专业知识、创造力和远见使他成为CA最新编辑的最佳人选。我确定CA在 Dizon 博士与现任主编、医学博士 Arif Kamal 的领导下未来的成功，并期待以读者而不是编辑的身份在线阅读未来的文章（尽管可能不会两次）。